Fulcrum Therapeutics (FULC) - רווח נקי למניה (EPS TTM)

Fulcrum Therapeutics develops innovative small molecules to correct genetic defects. Current earnings per share over the last 12 months demonstrate phases of capital consolidation, with this metric standing at -1.04. The company diversifies risks by developing treatments for blood and muscle pathologies. The strategy is based on independent clinical trials without engaging in mergers and acquisitions.
פילוחי מדדים מקיפים ואנליטיקה עבור Fulcrum Tx (FULC)

This indicator measures capital generation efficiency by dividing total annual net income by the total number of shares to determine the actual return per share. By analyzing the company's net income per share over 12 months, an investor assesses the financial stability of Fulcrum Therapeutics (FULC) against the development costs of losmapimod and its strategic partnership with Sanofi.